Aktis Oncology is a pre-profit biotech with 95.9% upside to the analyst target and 111% YoY revenue growth, but quality is below the 4.0 floor, the stock is 53% off its high, and short interest is 27%.
Thesis pillars
- Quality Below Floor→Stable
- Large Analyst Upside→Stable
- Single Lead Asset Concentration↑Improving
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026, based on the 10-K filed Mar 30, 2026
Aktis Oncology, Inc. (AKTS) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $15.20: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 7.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Below-average business quality; Negative price momentum.
Aktis Oncology is a clinical-stage biotechnology company developing miniprotein radioconjugates that deliver alpha-emitting radioisotopes to solid tumors, with lead candidate [225Ac]Ac-AKY-1189 targeting Nectin-4-expressing cancers in a Phase 1b trial. The company has not... Read more
Sell if holding. Engine safety override at $15.20: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 7.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Below-average business quality; Negative price momentum. Chart setup: Death cross but MACD improving, RSI 45. Score 5.8/10, moderate confidence.
Passes 5/9 gates (favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 7d<=7d. Suitability: speculative.
Recent developments
No fresh coverage since Oct 2, 2026
Recent Developments — Aktis Oncology, Inc.
Latest news
- NEWS Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target — benzinga Oct 2, 2026 positive
- NEWS Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519 — benzinga Oct 1, 2026 positive
- NEWS Oppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40 — benzinga Sep 9, 2026 positive
- NEWS Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35 — benzinga Aug 19, 2026 positive
- NEWS BMO Capital Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $37 — benzinga Aug 19, 2026 positive
Latest item Oct 2, 2026 · Generated 2026-11-05T11:44:07Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinelead product candidate [225Ac]Ac-AKY-118910-K Item 1A: 'Our business is highly dependent on our lead product candidate, [225Ac]Ac-AKY-1189, for the treatment of Nectin-4 expressing tumors.'
Material Events(8-K, last 90d)
- 2026-04-16Item 5.02LOWBoard appointed Glenn Gormley, MD, PhD as a Class I director effective April 15, 2026, and named him Co-Chair of the newly created Science and Technology Committee. Routine board appointment; no departure involved.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·2 ceiling hits
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $15.20: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 7.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Below-average business quality; Negative price momentum. Chart setup: Death cross but MACD improving, RSI 45. Prior stop was $14.14. Score 5.8/10, moderate confidence.
Analyst target: $31.21 (+105.3% upside). Prior stop was $14.14. Stop-loss: $14.14.
Concentration risk — Pipeline: lead product candidate [225Ac]Ac-AKY-1189; Quality below floor (3.4 < 4.0).
Aktis Oncology, Inc. trades at a P/E of N/A (forward -7.1). TrendMatrix value score: 9.0/10. Verdict: Sell.
16 analysts rate AKTS, with a consensus score of 4.4/5. 8 analysts publish price targets averaging $36.
What does Aktis Oncology, Inc. do?Aktis Oncology is a clinical-stage biotechnology company developing miniprotein radioconjugates that deliver...
Aktis Oncology is a clinical-stage biotechnology company developing miniprotein radioconjugates that deliver alpha-emitting radioisotopes to solid tumors, with lead candidate [225Ac]Ac-AKY-1189 targeting Nectin-4-expressing cancers in a Phase 1b trial. The company has not generated product revenue and funds operations through equity financings and a May 2024 discovery collaboration with Eli Lilly, which paid a $60.0 million upfront fee and could contribute up to $1.2 billion in milestones. Aktis held $226.8 million in cash as of December 31, 2025, plus $335.3 million in IPO proceeds from its J